Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma

Tatiana Pazina, Ashley M. James, Kimberly B. Colby, Yibin Yang, Andrew Gale, Amy Jhatakia, Alper Y. Kearney, Robert F. Graziano, Natalie A. Bezman, Michael D. Robbins, Adam D. Cohen and Kerry S. Campbell
Tatiana Pazina
1Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
2FSBSI “Institute of Experimental Medicine,” St. Petersburg, Russia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ashley M. James
1Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ashley M. James
Kimberly B. Colby
1Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yibin Yang
1Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Gale
1Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andrew Gale
Amy Jhatakia
3Bristol-Myers Squibb, Princeton, New Jersey.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alper Y. Kearney
3Bristol-Myers Squibb, Princeton, New Jersey.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert F. Graziano
3Bristol-Myers Squibb, Princeton, New Jersey.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natalie A. Bezman
3Bristol-Myers Squibb, Princeton, New Jersey.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael D. Robbins
3Bristol-Myers Squibb, Princeton, New Jersey.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adam D. Cohen
4Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Adam D. Cohen
  • For correspondence: kerry.campbell@fccc.edu adam.cohen@uphs.upenn.edu
Kerry S. Campbell
1Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kerry S. Campbell
  • For correspondence: kerry.campbell@fccc.edu adam.cohen@uphs.upenn.edu
DOI: 10.1158/2326-6066.CIR-18-0579 Published October 2019
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Elotuzumab promoted maximal ADCC if NK cells expressed high-affinity CD16 and required SLAMF7 expression on MM cells. A, Comparison of CD16 expression (GRM1 antibody, Southern Biotech) on parental NK-92 cells (CD16−; gray) and NK-92 cells transduced to express 176V (solid line) or 176F (dashed) polymorphic variants of CD16, and mean GMFI ± SD from five experiments (bottom). B, SLAMF7 expression before and after the genetic modification of two human MM cell lines (Elo + anti-IgG1 secondary stain). MM.1R cells were transfected with SLAMF7 zinc finger nucleases (ZFN) to genetically deplete SLAMF7 (MM.1R SLAMF7KO; left), and RPMI8226 cells were stably transduced with SLAMF7 cDNA (RPMI8226+SLAMF7; right), and mean GMFI ± SD from five experiments (bottom). Cells were stained with biotinylated Elo plus secondary streptavidin–APC. C and D, Effect of SLAMF7 expression on NK cell–mediated ADCC in the presence of various concentrations of Elo (0.001–300 μg/mL). Values are mean ± S D. Asterisks indicate statistical significance comparing cytotoxicity by NK-92 cells expressing 176V or 176F variants of CD16 using Welch unequal variance t test. *, P < 0.05; n = 5 independent experiments.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Elotuzumab enhances natural cytotoxicity by NK cells in a CD16-independent manner. A, Effect of Elo (0.001–300 μg/mL) on natural cytotoxicity of parental NK-92 cells expressing SLAMF7 and lacking CD16 (SLAMF7+, CD16−), toward MM.1R (top) and RPMI8226 (bottom) cells. Gray squares are genetically modified MM.1R SLAMF7KO (top) or RPMI83226 + SLAMF7 (bottom) targets. Values are mean ±SD. Overhead bars mark statistical significance between untreated and different Elo concentration groups using paired Student t test. **, P < 0.01; *, P < 0.05; n = 5 independent experiments. B, SLAMF7 expression on parental SKOV3 cells (solid line) and SKOV3 cells that were stably transduced with SLAMF7 cDNA (dashed line) and stained with the 162.1 SLAMF7 antibody (BioLegend), and mean GMFI ± SD from five experiments (bottom). C, Kinetics of parental SKOV3 (top graph) or SKOV3(+SLAMF7; bottom graph) target cell death by parental NK-92 cells (SLAMF7+, CD16−) analyzed in xCELLigence assays. n = 4–6. D, Mean, SD, and statistical analysis for percentage target cell death (compared with detergent lysis conditions as 100%) at 10 hours of xCELLigence assays from four to six independent experiments. Overhead bars mark statistical comparison between indicated groups using paired Student t test; **, P < 0.01; *, P < 0.05. E, Schematic of Elo effect on the cytotoxicity of NK cells against SLAMF7+ and SLAMF7− targets.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Elotuzumab is unable to enhance natural cytotoxicity of NK cells lacking expression of both SLAMF7 and CD16. A, SLAMF7 expression (162.1 SLAMF7 antibody, BioLegend) on NK-92 control (GFP knockout, SLAMF7+, CD16−; solid line) and NK-92 SLAMF7 KO (CD16−; dashed line) cells generated using CRISPR/Cas9, and mean GMFI ± SD from five experiments (bottom). B, Cytotoxicity toward SKOV3(+SLAMF7) target cells by NK-92 (SLAMF7+, CD16−) and NK-92 (SLAMF7 KO, CD16−) cells studied over time in xCELLigence assays with or without Elo (10 μg/mL; top) or Elo Fc mutant (Elo Fc mut; 10 μg/mL; bottom). C, Mean ± SD target cell death at 10 hours from xCELLigence assays for Elo (top) and Elo Fc mut (bottom) toward SKOV3(+SLAMF7) target cells from four to five independent experiments. Overhead bars mark statistical comparison between indicated groups using paired Student t test. **, P < 0.01; *, P < 0.05. D, Cytotoxicity toward SKOV3(+SLAMF7) target cells by NK-92 (SLAMF7+, CD16−) cells studied over time in xCELLigence assays (top) and mean ±SD target cell death at 10 hours (bottom) for Elo versus Elo F(ab')2 versus Fab (3 and 10 μg/mL). Overhead bars mark statistics as in C. n = 4 independent experiments. E, Schematic showing requirement for SLAMF7 expression on NK cells for CD16-independent NK cell–mediated cytotoxicity.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Elotuzumab uniquely promotes SLAMF7–SLAMF7 interactions. A, SLAMF7-TCRζ reporter cell line was cultured with four different plate-bound SLAMF7 antibodies (Elo, ChuLuc90, PDL241, and 162.1; coated overnight at 10 μg/mL) and mouse IL2 (mIL2) was assayed in culture supernatant. B, Indicated SLAMF7 antibodies or isotype controls (0.01–3 μg/mL) were added to 3A9 SLAMF7-TCRζ reporter cell line in plates coated with recombinant human SLAMF7 (hSLAMF7) overnight, and mIL2 secretion was assayed. C, Soluble Elo (left) or hIgG1 isotype control (right) were added to SLAMF7-TCRζ reporter cell line on plate-bound (PB) recombinant hSLAMF7 or PB mesothelin control protein, or hSLAMF7 was added as soluble protein (+hSLAMF7; right). Plotted as mean ± SEM.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Elotuzumab promotes costimulation-mediated cytotoxicity. Impact of various SLAMF7 antibodies (10 μg/mL each) on cytotoxicity by NK-92(SLAMF7+,CD16−) cells (A) or SLAMF7-deficient NK-92 (SLAMF7 KO, CD16−) cells (B) toward SKOV3(+SLAMF7) target cells in xCELLigence assays. Mean, SD; and statistics for target cell death are shown at 10 hours from three to four independent xCELLigence assays. Overhead bars mark statistical significance between indicated groups using paired Student t test. **, P < 0.01; *, P < 0.05. ns, not significant. Elo, elotuzumab; CL90, ChLuc90; 162, 162.1; P241, PDL241. C and D, Test of the impact of blocking NKG2D (C) and DNAM1 (D) antibodies on Elo-induced cytotoxicity by NK-92(SLAMF7+, CD16−) cells toward SKOV3(+SLAMF7) target cells in xCELLigence assays. Mean, SD; statistics for target cell death at 10 hours from five independent assays using blocking antibodies at 10 μg/mL each. Overhead bars mark statistics as in A and B. Kinetic plots for all of these xCELLigence assays can be found in Supplementary Fig. S5C and S5D.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    Elotuzumab enhances NK cell cytotoxicity only if SLAMF7 contains the full cytoplasmic domain. A, Representative SLAMF7 expression (162.1 antibody, BioLegend) on NK-92 SLAMF7 KO cells (gray) and reconstituted with SLAMF7-L (dashed) or SLAMF7-S (solid line) isoforms, and mean GMFI ± SD from five experiments (bottom). B, Impact of Elo (10 μg/mL) on cytotoxicity by NK-92(SLAMF7 KO, CD16−) cells reconstituted with either SLAMF7-L or SLAMF7-S toward SKOV3(+SLAMF7) target cells studied in xCELLigence assays. C, Mean, SD; statistics for target cell death at 10 hours from five independent assays. Overhead bars mark statistical comparisons between indicated groups using paired Student t test. *, P < 0.05.

  • Figure 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7.

    Costimulation of healthy donor NK cell cytotoxicity by Elo Fc mut depends on NK cell activation status. A, Elo or Elo Fc mut (10 μg/mL) was added to SKOV3(+SLAMF7) target cells in the presence or absence of freshly purified NK cells from healthy donor (HD) #1 in xCELLigence assays. B, Compilation of cytotoxicity data for n = 7 healthy donors. Percentage target cell death at the 10-hour time point from xCELLigence assays in the absence (−) or presence (+) of Elo Fc mut by purified NK cells toward SKOV3(+SLAMF7) target cells on the day of the purification (left) or after cultured in the presence of recombinant human IL2 (100 U/mL; +) for 48 hours (right). Each patient is designated by a unique icon, and results with or without antibody addition are connected with lines. Overhead bars mark statistical comparison between indicated groups using Wilcoxon matched-pairs signed rank test. C and D, Representative time course data in which purified NK cells from HD#3 and HD#8 were assayed fresh (left) or after cultured in the presence of recombinant human IL2 (100 U/mL) for 48 hours (right).

Additional Files

  • Figures
  • Supplementary Data

    • Supplementary Data - Supplementary Figures 1-9
PreviousNext
Back to top
Cancer Immunology Research: 7 (10)
October 2019
Volume 7, Issue 10
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma
Tatiana Pazina, Ashley M. James, Kimberly B. Colby, Yibin Yang, Andrew Gale, Amy Jhatakia, Alper Y. Kearney, Robert F. Graziano, Natalie A. Bezman, Michael D. Robbins, Adam D. Cohen and Kerry S. Campbell
Cancer Immunol Res October 1 2019 (7) (10) 1633-1646; DOI: 10.1158/2326-6066.CIR-18-0579

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma
Tatiana Pazina, Ashley M. James, Kimberly B. Colby, Yibin Yang, Andrew Gale, Amy Jhatakia, Alper Y. Kearney, Robert F. Graziano, Natalie A. Bezman, Michael D. Robbins, Adam D. Cohen and Kerry S. Campbell
Cancer Immunol Res October 1 2019 (7) (10) 1633-1646; DOI: 10.1158/2326-6066.CIR-18-0579
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • CD28 Mutation Enhances CAR T-cell Function
  • ICV-Delivered CD19-CAR T Cells for CNS and Systemic Lymphoma
  • Activin A Mediates Radiation-Induced Antitumor Immunity
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement